Edwards Lifesciences
1,273 hedge funds and large institutions have $48.2B invested in Edwards Lifesciences in 2022 Q2 according to their latest regulatory filings, with 114 funds opening new positions, 447 increasing their positions, 480 reducing their positions, and 137 closing their positions.
0.06% less ownership
Funds ownership: 81.89% → 81.82% (-0.06%)
7% less call options, than puts
Call options by funds: $182M | Put options by funds: $195M
7% less repeat investments, than reductions
Existing positions increased: 447 | Existing positions reduced: 480
3% less funds holding
Funds holding: 1,315 → 1,273 (-42)
15% less funds holding in top 10
Funds holding in top 10: 26 → 22 (-4)
17% less first-time investments, than exits
New positions opened: 114 | Existing positions closed: 137
19% less capital invested
Capital invested by funds: $59.6B → $48.2B (-$11.3B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$313M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$236M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$187M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$129M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$224M |
| 2 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$158M |
| 3 |
BlackRock
New York
|
-$133M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$122M |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$101M |
EW Hedge Fund Activity: Q2 2022 in Review
1,273 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2022, worth a combined $48.2B — down 19% from $59.6B a quarter earlier.
Sellers outnumbered buyers: 137 funds closed out of EW and 114 opened new positions — a net loss of 23 holders — while 480 trimmed existing stakes and 447 added.
The largest buyer was Morgan Stanley, adding an estimated $313M. The largest seller was Janus Henderson Group, cutting an estimated $224M.
- 1,273 institutional investors held Edwards Lifesciences (EW) as of Q2 2022, down from 1,315 in Q1 2022.
- Funds reported $48.2B of Edwards Lifesciences stock for Q2 2022, down 19% quarter-over-quarter.
- 114 funds opened new Edwards Lifesciences positions in Q2 2022 and 137 closed out, a net change of -23 holders.
- The largest Edwards Lifesciences buyer in Q2 2022 was Morgan Stanley, an estimated $313M added.
- The largest Edwards Lifesciences seller in Q2 2022 was Janus Henderson Group, an estimated $224M sold.
Based on aggregated 13F filings for Q2 2022.